A Study of ADRX-0706 in Select Advanced Solid Tumors

Inclusion Criteria:

• Phase 1a Dose Escalation: Subjects with histologically confirmed select advancedsolid tumors, including urothelial carcinoma (UC), head and neck squamous cellcarcinoma (HNSCC), breast cancer, cervical cancer, ovarian cancer, non-small celllung cancer (NSCLC), and pancreatic cancer. Subjects must have received at least oneprior systemic regimen and have no other therapy available known to providemeaningful clinical benefit in the opinion of the investigator.

• Phase 1b Dose Expansion: Subjects with urothelial cancer, triple negative breastcancer or cervical cancer with disease progression after at least one prior systemicregimen and no standard treatment options available and considered appropriate inthe opinion of the investigator, unless subject refuses standard therapy.

• Measurable disease according to RECIST version 1.1

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Adequate hematologic, liver, and renal function

Exclusion Criteria:

• Active and uncontrolled central nervous system metastases

• Significant cardiovascular disease

• History of another malignancy other than the one for which the subject is beingtreated on this study within 3 years

• Receipt of any anticancer or investigational therapy within 5 elimination half-livesor 14 days (whichever is less)

• Any P-gp inducers/inhibitors or strong CYP3A inhibitors received within 14 daysprior to the first dose of study drug

• Receiving systemic antimicrobial treatment for active infection; routineantimicrobial prophylaxis is permitted